Form 4: ONCY Director Boosts Stake with Share Purchases
Insider Transaction Report
ONCOLYTICS BIOTECH Director Bernd R. Seizinger acquired 100,000 common shares through two open market purchases in February 2026.
Summary
- Bernd R. Seizinger, a Director of ONCOLYTICS BIOTECH INC (ONCY), purchased a total of 100,000 common shares.
- The first transaction occurred on February 11, 2026, involving the acquisition of 60,000 common shares at a price of $0.8265 per share.
- The second transaction took place on February 12, 2026, where an additional 40,000 common shares were acquired at $0.8466 per share.
- Following these transactions, Mr. Seizinger directly beneficially owns 566,991 common shares.
- The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development. Insider buying indicates confidence from a company director, which is generally a bullish signal, though the magnitude of the purchase relative to the company's market cap and the director's total holdings would provide further context.
Positives
- A Director increasing their stake in the company through open market purchases signals confidence in the company's future prospects and valuation.
- The purchases were made under a Rule 10b5-1 plan, which suggests a pre-planned investment strategy rather than a reaction to immediate news.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance.
Industry Context
StockSavvy.ai notes that insider buying, particularly from a Director, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or expect positive developments. This can sometimes precede periods of stock appreciation, though it is not a guarantee.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | N/A | This indicates a pre-arranged trading plan, reducing the perception that the purchases were made based on immediate, non-public information, and aligning with best practices for insider trading compliance. |
Stakeholder Impact
- Shareholders: Increased ownership by a director can align management interests more closely with those of shareholders, potentially fostering greater confidence in the company's leadership and future direction.
Key Dates
| Date | Description |
|---|---|
| 02/11/2026 | Transaction date for the acquisition of 60,000 common shares by Bernd R. Seizinger. |
| 02/12/2026 | Transaction date for the acquisition of 40,000 common shares by Bernd R. Seizinger. |
| 02/13/2026 | Date the Statement of Changes in Beneficial Ownership (Form 4) was signed. |
Recommendation
buyA seasoned investor or institution would likely view this insider buying as a positive indicator. When a director, who has intimate knowledge of the company's operations and prospects, increases their personal stake, it suggests a belief that the stock is undervalued or that significant positive developments are anticipated. While not a standalone reason to buy, it adds a layer of confidence to the investment thesis for ONCOLYTICS BIOTECH.
Keywords
ONCOLYTICS BIOTECH, ONCY, insider buying, director purchase, common shares, beneficial ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.